ORIGINAL ARTICLE
Assessing the budget impact of nintedanib for the treatment of idiopathic pulmonary fibrosis in the Greek healthcare setting
 
More details
Hide details
1
University of Peloponnese, Corinth, Greece
2
Health Policy Institute, Athens, Greece
3
University of Athens, Athens, Greece
CORRESPONDING AUTHOR
Demosthenes Bouros   

First Academic Department of Pneumonology, Hospital for Diseases of the Chest, “Sotiria”, Medical School, National and Kapodistrian University of Athens 152 Messogion Aven., Athens 11527, Greece
 
Pneumon 2018;31(4):205–211
 
KEYWORDS
ABSTRACT
Idiopathic pulmonary fibrosis (IPF) is a rare, chronic lung disease with a high mortality rate. IPF affects about 5 million people worldwide with median survival being 2-5 years following diagnosis. Until recently, there was no licensed pharmacologic therapy available for IPF and patients were managed by best supportive care, that includes treatment with pirfenidone. In 2015, nintedanib was approved for the treatment of IPF. This study estimates the reimbursement of nintedanib and its budget impact on the National Organization for Health Care Services Provision (EOPPY). The budget impact of reimbursing nintedanib as part of already available treatment options corresponds to a maximum of 0.13% of annual total pharmaceutical expenditure. Therefore, it has a relatively low impact on the budget of EOPPY, while use of nintedanib was associated with a higher number of acute exacerbation events being avoided, thus providing additional cost savings to EOPPY.
CONFLICTS OF INTEREST
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
FUNDING
This paper was not funded.
 
REFERENCES (17)
1.
Fala L. Ofev (Nintedanib): First tyrosine kinase inhibitor approved for the treatment of patients with idiopathic pulmonary fibrosis. Am Health Drug Benefits 2015; 8(Spec Feature):101–4.
 
2.
Karakatsani A, Papakosta D, Rapti A, et al. Hellenic Interstitial Lung Diseases Group Epidemiology of interstitial lung diseases in Greece. Respir Med 2009;103:1122–9.
 
3.
Kistler KD, Nalysnyk L, Rotella P, et al. Lung transplantation in idiopathic pulmonary fibrosis: a systematic review of the literature. BMC Pulm Med 2014;14:139. doi: 10.1186/1471-2466-14-139.
 
4.
Kreuter M, Ehlers-Tenenbaum S, Palmowski K, et al. Impact of Comorbidities on Mortality in Patients with Idiopathic Pulmonary Fibrosis. PLoS One 2016;11(3):e0151425. doi: 10.1371/journal. pone.0151425.eCollection 2016.
 
5.
Ley B, Collard HR. Epidemiology of idiopathic pulmonary fibrosis. Clin Epidemiol 2013;5:483-92. doi: 10.2147/CLEP.S54815.
 
6.
Meltzer EB, Noble PW. 2008. Idiopathic Pulmonary fibrosis. Orphanet J Rare Dis 2008; 26;3:8. doi: 10.1186/1750-1172-3-8. available at: http://www.orpha.net/consor/cg....
 
7.
Nalysnyk L, Cid-Ruzafa J, Rotella P, et al. Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature. European Respiratory Review 2012;21:355-61.
 
8.
National Institute for Health and Care Excellence. Diagnosis and management of suspected idiopathic pulmonary fibrosis. Clinical Guideline. Methods, evidence and recommendations. Idiopathic pulmonary fibrosis: full guideline draft. January 2013. http://www.nice.org.uk/nicemed....
 
9.
National Institute for Health and Care Excellence. Evidencebased recommendations on nintedanib (Ofev) for adults with idiopathic pulmonary fibrosis. NICE technology appraisal guidance [TA379] Published date: 27 January 2016.
 
11.
Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011;377:1760–69.
 
12.
OECD, 2016. Demography and Population available at: http:// stats.oecd.org/Index.aspx?Data....
 
13.
Raghu G, Selman M. Nintedanib and pirdenidone. New antifibrotic treatment indicated for idiopathic pulmonary fibrosis offer hopes and raises questions. Am J Respir Crit Care Med 2015;191:252-4. doi: 10.1164/rccm.201411-2044ED.
 
14.
Richeldi L, du Bois RM, Raghu G, et al. INPULSIS Trial Investigators. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014;29;370:2071-82.
 
15.
Rinciog D, Watkins M, Chang S, et al. A cost-effectiveness analysis of nintedanib in idiopathic pulmonary fibrosis in the UK. Pharmaco Economics 2017; 35:479-91. doi: 10.1007/ s40273-016-0480-2.
 
16.
Yanni F. Yu, Ning Wu, Chien-Chia Chuang, et al. Patterns and economic burden of hospitalizations and exacerbations among patients diagnosed with idiopathic pulmonary fibrosis. J Manag Care Spec Pharm 2016;22:414-23.
 
17.
Greek legislated DRGs 2012-2017 - Υ4α/οικ.105494 ΚΥΑ (ΦΕΚ 3096/Β/2012), Υ4α/οικ.50142 ΚΥΑ (ΦΕΚ 1474/Β/2014), Α3γ/ οικ.76490 ΚΥΑ (ΦΕΚ 3395/Β/2016), Α3γ/οικ.1846 ΚΥΑ (ΦΕΚ 117/Β/2017).
 
eISSN:1791-4914
ISSN:1105-848X